2009Zhongguo yiyuan ganranxue zazhiRequires access

Comparison of Moxifloxacin and Cefuroxime Combined with Azithromycin for Patients with Community-acquired Pneumonia

Zhenshun Chen

Open publisher page 1 citations

Abstract

OBJECTIVE To evaluate the efficacy,the eradication rates of pathogens and safety of moxifloxacin in patients with community-acquired pneumonia(CAP) in comparison with therapy using a combination of cefuroxime plus azithromycin.METHODS Seventy eight patients with CAP were randomly divided into two groups:moxifloxacin alone and cefuroxime plus azithromycin,and the efficacy,the eradication rates of pathogens and the rates of side effects were observed.RESULTS From 40 patients in the moxifloxacin group,32 patients(80%) were clinically cured and 6 patients(15%)were improved.And from 38 patients in the cefuroxime plus azithromycin groups,30 patients(78.9%) were clinically cured and 5 patients(13.2%) were improved.The eradication rates of pathogens were 89% and 84%,respectively.And the rates of side effects were 7.5% and 7.9%,respectively.CONCLUSIONS There are no significant differences in the efficacy,the eradication rates of pathogens and safety between 2 groups in treating community-acquired pneumonia.

About this research paper

What this paper is about

OBJECTIVE To evaluate the efficacy,the eradication rates of pathogens and safety of moxifloxacin in patients with community-acquired pneumonia(CAP) in comparison with therapy using a combination of cefuroxime plus azithromycin.METHODS Seventy eight patients with CAP were randomly divided into two groups:moxifloxacin alone and cefuroxime plus azithromycin,and the efficacy,the eradication rates of pathogens and the rates of side effects were observed.RESULTS From 40 patients in the moxifloxacin group,32 patients(80%) were clinically cured and 6 patients(15%)were improved.And from 38 patients in the cefuroxime plus azithromycin groups,30 patients(78.9%) were clinically cured and 5 patients(13.2%) were improved.The eradication rates of pathogens were 89% and 84%,respectively.And the rates of side effects were 7.5% and 7.9%,respectively.CONCLUSIONS There are no significant differences in the efficacy,the eradication rates of pathogens and safety between 2 groups in treating community-acquired pneumonia.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE To evaluate the efficacy,the eradication rates of pathogens and safety of moxifloxacin in patients with community-acquired pneumonia(CAP) in comparison with therapy using a combination of cefuroxime plus azithromycin.METHODS Seventy eight patients with CAP were randomly divided into two groups:moxifloxacin alone and cefuroxime plus azithromycin,and the efficacy,the eradication rates of pathogens and the rates of side effects were observed.RESULTS From 40 patients in the moxifloxacin group,32 patients(80%) were clinically cured and 6 patients(15%)were improved.And from 38 patients in the cefuroxime plus azithromycin groups,30 patients(78.9%) were clinically cured and 5 patients(13.2%) were improved.The eradication rates of pathogens were 89% and 84%,respectively.And the rates of side effects were 7.5% and 7.9%,respectively.CONCLUSIONS There are no significant differences in the efficacy,the eradication rates of pathogens and safety between 2 groups in treating community-acquired pneumonia.

Key concepts: Moxifloxacin, Cefuroxime, Azithromycin, Medicine, Community-acquired pneumonia, Pneumonia, Internal medicine, Antibiotics

Related papers

Back to paper searchBrowse research topicsOriginal source
Comparison of Moxifloxacin and Cefuroxime Combined with Azithromycin for Patients with Community-acquired Pneumonia — Research Paper | ScholarLens